-+ 0.00%
-+ 0.00%
-+ 0.00%

NATERA SUBMITS SIGNATERA™ TO JAPAN’S PMDA FOR APPROVAL AS A COMPANION DIAGNOSTIC IN MUSCLE-INVASIVE BLADDER CANCER

Reuters·08/05/2026 10:09:43

Please log in to view news